Ranbaxy owns many such products. Then there is the company's branded products business in the United States, which is unaffected by the FDA alerts and is over $100 million in size. Sun Pharma, it is learnt, has chalked out a detailed turnaround plan for its new purchase. According to sources, it has prepared a three-pronged strategy which includes integration of supply chain and field force for enhanced efficiency and productivity, resolution of regulatory issues and higher growth through synergy in domestic and emerging markets. Sun Pharma declined to comment for this report. However, sources say the company is targeting a three- to four-year period after the closure of the transaction to engineer the full turnaround of Ranbaxy. Sun Pharma is expecting to close the deal by December. "The merger of the functions of two companies of this size could be a major challenge. The first step will be to streamline and rationalise functions.